Merck : Phase 3 Study Of KEYTRUDA – Chemotherapy On Metastatic Esophageal Cancer Meets Main Goal

Merck & Co., Inc.(MRK) said that the pivotal Phase 3 KEYNOTE-590 trial evaluating the company’s anti-PD-1 therapy KEYTRUDA in combination with chemotherapy met its primary endpoints of overall survival or OS and progression-free survival or PFS for the first-line treatment of patients with locally advanced or metastatic esophageal cancer.

https://www.nasdaq.com/articles/merck-%3A-phase-3-study-of-keytruda-chemotherapy-on-metastatic-esophageal-cancer-meets-main

Leave a comment



Leave a Reply

Your email address will not be published. Required fields are marked *